A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
All eligible patients will receive the study treatment at selected oral dose(s) oncedaily. Patients will be treated continuously until disease progression or any otherpre‐defined discontinuation criteria are met.
Epistemonikos ID: 4fd3a72b580bf32583e768dc58a6903c02eff138
First added on: May 15, 2024